Acme United Corporation (ACU), a steady player in cutting tools, first aid kits, and office products, has been navigating a post-pandemic world with resilient revenue growth but some profitability bumps along the way. As everyday investors, we’re often drawn to small-cap names like this one for their potential to punch above their weight, especially when fundamentals show a mix of expansion and cautionary tales. Over the past decade, ACU’s sales have climbed impressively, roughly doubling from $125 million in 2016 to $194 million in 2024—a compound annual growth rate hovering around 6%—fueled by demand surges during COVID for home office and safety gear. Yet, net income has been a rollercoaster, peaking at $17.8 million in 2023 before dipping 44% to $10 million in 2024. This volatility ties into broader events like supply chain snarls in 2022 and a first-aid product recall in late 2021 that briefly dented margins, but the company rebounded strong. Today, with shares trading near recent levels, let’s unpack the numbers to see if this is a buy, hold, or pass for your portfolio.
Revenue Growth: Steady Climb with Efficiency Tweaks
Revenue tells a reliable growth story here, expanding from $130.6 million in 2017 to $194.5 million in 2024, a 49% increase over seven years. That’s meaningful because consistent top-line growth signals market share gains in niche areas like medical supplies and shearing tools, where ACU holds a solid position. Employee count rose from 421 in 2017 to a peak of 654 in 2021 amid pandemic hiring, then stabilized around 633 in 2024—revenue per employee dipped slightly to $307,000 but remains healthy, showing productivity holds up without massive headcount bloat.
Analysts project this momentum continues: $196 million in 2025 (up 1%), $206 million in 2026 (5% jump), and $216 million in 2027 (5% more). That’s conservative but believable, correlating with broader recovery in office and consumer spending post-2023 inflation peaks. Stock price action mirrors this—lows and highs climbed from $20-$29 in 2017 to $33-$51 in 2024, a multi-fold gain—suggesting investors rewarded the revenue reliability even as profits wobbled.
Profitability: Peaks, Valleys, and Margin Expansion
Digging into the bottom line, earnings per share (EPS) soared to $4.98 in 2023 from $0.86 in 2022—a whopping 479% surge—driven by $22.7 million in EBT (up 520% from prior year), thanks to gross margins ballooning to 37.7%. Gross margin is key here: it measures pricing power and cost control after direct expenses, and ACU’s climb to 39.3% in 2024 (from 32.8% in 2022) reflects better sourcing and premium product mixes amid easing raw material costs post-Ukraine war disruptions.
But 2024 brought a reality check—EBT margin fell to 6.3% (down 47% from 2023’s 11.9%), with net income dropping 44% to $10 million and EPS to $2.71. ROE, a favorite for gauging shareholder returns, mirrored this at 20.1% in 2023 before halving to 9.8%. Cash flow per share spiked to $8.09 in 2023 on $29 million operating cash (up 897%), funding $23.9 million free cash flow—a boon for reinvestment. Yet 2024’s free cash flow per share settled at $1.30 after $4.8 million FCF, with capex at $7.1 million (up 43% YoY), signaling ongoing factory upgrades.
Future outlook tempers enthusiasm: EPS projected at $2.41 in 2025 (down 11%), $1.62 in 2026 (33% drop), and $1.73 in 2027 (7% rebound). EBT dips to $8.4 million in 2025, but revenue per share rises steadily to $56.84 by 2027. This suggests margin pressure from investments or competition, but improving gross margins could stabilize ROA around 4%—still decent for a manufacturer.
Balance Sheet Strength: Debt Tamed, Equity Built
ACU’s fortress-like balance sheet supports growth without excessive risk. Shareholders’ equity ballooned from $46 million in 2016 to $107 million in 2024 (132% growth), boosting book value per share to $28.91 (up 109%). Total debt peaked at $61 million in 2022 amid expansion but plunged 59% to $23.8 million in 2023, then up modestly 17% to $27.9 million in 2024—net debt followed suit, down to $21.5 million. This deleveraging is crucial: lower debt eases interest burdens (implied in EBT), freeing cash for dividends or buybacks.
Working capital sits comfortably at $72.6 million in 2024, covering ops smoothly. ROIC held steady around 6-7% most years, dipping to 2.9% in 2022’s rough patch but rebounding—evidence of efficient capital use. Stock multiples reflect this safety: PB ratio averaged ~1.4x, spiking low to 0.92x in 2018 when shares undervalued the equity build.
Valuation Snapshot: Reasonable but Not Screaming Cheap
At recent levels, ACU’s PE stands at about 14x trailing EPS, in line with historical averages (8-25x range), while PS ~0.7x and EV/Sales ~0.82x suggest fair pricing for growth. EV/FCF varies wildly due to cash flow swings but averages mid-teens lately. Compared to revenue trajectory, shares have kept pace—2023’s profit boom pushed highs near 45% above prior year lows, but 2024’s pullback saw lows ~37% below 2023 peaks. Still, from 2016’s sub-27 highs to 2024’s 51 peak, that’s ~91% appreciation, outpacing revenue growth thanks to margin tailwinds.
Analyst price targets cluster tightly: low implies ~7% upside from recent close, mean ~10% upside, high ~13% upside. That’s not fireworks, but for a steady grower, it’s a vote of confidence amid small-cap volatility.
Insider Activity: Sells, No Buys—Watch Closely
Insider transactions raise a yellow flag: zero buys across 2025-early 2026, but sells totaling ~$409,000 by the President and COO—7,423 shares in April ($297k, reducing holdings to 44k), 996 in May ($40k, to 43k), and 1,810 in June ($72k, to 41k). No other activity monthly. Insiders selling post-profit peaks isn’t uncommon (locking gains after 2023’s run-up), but absence of buys amid projected EPS softness warrants caution. It doesn’t scream distress—holdings remain substantial—but correlates with tempered future NI forecasts.
Stock Price Evolution vs. Fundamentals: Aligned but Volatile
Price lows/highs track fundamentals well: 2020-2021 COVID boom saw lows jump 118% ($17 to $30), highs 79% ($35 to $48), aligning with revenue’s 18% and 11% growth spurts. 2022 dip (lows down 29%, highs 26%) matched NI plunge 78% and margin crush to 32.8%. 2023 recovery exploded prices (lows up 56%, highs 26%) with NI tripling. 2024’s high of ~51 (up 14% from 2023) held gains despite profit fade, buoyed by debt cuts and cash pile.
Recent close reflects stabilization ~14% above 2024 low, ~13% below high—poised for analyst-projected revenue push if margins hold.
Looking Ahead: Modest Growth with Risks
Analysts see revenue compounding ~5% annually through 2027, but EPS volatility persists—down to $1.62 mid-period before ticking up. Shares outstanding creep to 3.81 million, diluting slightly, but buybacks could counter. Key drivers: first-aid demand from workplace safety regs, e-commerce expansion (a post-2020 tailwind), and Asia manufacturing efficiencies cutting costs.
Risks loom—2022-like margin squeezes from inflation or recalls (remember the 2021 first-aid hiccup?), plus insider sells hinting caution. Yet, with ROE forecasted ~9%, debt low, and FCF positive, ACU suits patient investors eyeing 10% annual returns. If revenue hits projections and margins reclaim 39%, shares could outperform targets by 20%+ in 2-3 years.
Bottom line for retail folks: ACU’s no moonshot, but its fundamentals scream reliability over flash. Hold if owned; nibble on dips if targets materialize. Track Q1 2026 earnings for insider vibes and margin clues—your portfolio will thank the homework.
(Word count: 1,128)